Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 16, 2021 06:45 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Pricing of Public Offering

EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...
September 04, 2019 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference

EDISON, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
September 03, 2019 16:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

EDISON, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
August 14, 2019 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431

EDISON, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
August 07, 2019 13:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board

EDISON, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
July 31, 2019 09:20 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta

- Accelerating NASH Research Programs - EDISON, N.J., July 31, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of...
July 29, 2019 16:15 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH

EDISON, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
July 22, 2019 14:00 ET | Source: ContraVir Pharmaceuticals Inc.

ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA”

EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
June 27, 2019 08:00 ET | Source: ContraVir Pharmaceuticals Inc.

ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH

EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
June 20, 2019 16:30 ET | Source: ContraVir Pharmaceuticals Inc.

ContraVir Pharmaceuticals Receives Positive FDA Response to CRV431 Pre-IND Package for NASH

EDISON, N.J., June 20, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right